For the quarter ended September 2026, Ashland (ASH Quick QuoteASH - Free Report) reported revenue of $498 million, up 4.2% over the same period last year. EPS came in at $1.12, compared to $1.08 in the year-ago quarter.

The reported revenue compares to the Zacks Consensus Estimate of $500.66 million, representing a surprise of -0.53%. The company delivered an EPS surprise of -13.85%, with the consensus EPS estimate being $1.30.

While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.

As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.

Here is how Ashland performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

• Revenue- Intermediates: $33 million versus $35.03 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a 0% change.
• Revenue- Life Sciences: $180 million versus the three-analyst average estimate of $183.64 million. The reported number represents a year-over-year change of +4.1%.
• Revenue- Personal Care: $163 million versus the three-analyst average estimate of $157.93 million. The reported number represents a year-over-year change of +8%.
• Revenue- Specialty Additives: $131 million compared to the $137.03 million average estimate based on three analysts. The reported number represents a change of 0% year over year.
• Revenue- Intersegment sales: $-9 million compared to the $-10 million average estimate based on two analysts. The reported number represents a change of -10% year over year.
• Adjusted EBITDA- Life Science: $64 million compared to the $60.77 million average estimate based on three analysts.
• Adjusted EBITDA- Personal Care: $49 million compared to the $49.62 million average estimate based on three analysts.
• Adjusted EBITDA- Specialty Additives: $20 million compared to the $23.35 million average estimate based on three analysts.
• Adjusted EBITDA- Intermediates: $6 million compared to the $4.37 million average estimate based on three analysts.
• OPERATING INCOME- Unallocated and other: $-44 million compared to the $-15.5 million average estimate based on two analysts.

View all Key Company Metrics for Ashland here>>>

Shares of Ashland have returned +7.9% over the past month versus the Zacks S&P 500 composite's -2.3% change. The stock currently has a Zacks Rank #4 (Sell), indicating that it could underperform the broader market in the near term.